Transcobalamin polymorphism and serum holo-transcobalamin in relation to Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 17, Issue 3, 2004, Pages 215-221

  McCaddon, Andrew ^a   Blennow, Kaj ^f   Hudson, Peter ^b   Hughes, Alan ^c   Barber, Joan ^d   Gray, Rob ^c   Davies, Gareth ^b   Williams, John H H ^e   Duguid, Jennifer ^b   Lloyd, Alwyn ^b   Tandy, Steve ^b   Everall, Marge ^b   Cattell, Howard ^b   McCaddon, Anne ^a   Ellis, Dick ⁱ   Palmer, Mona ^g   Bogdanovic, Nenad ^h   Gottfries, Carl Gerhard ^f   Zetterberg, Henrik ^g   Rymo, Lars ^g   Regland, Björn ^f   more..

^a GLYNDWR UNIVERSITY   (United Kingdom)

^b WREXHAM MAELOR HOSPITAL   (United Kingdom)

^c ROYAL ALEXANDRA HOSPITAL   (United Kingdom)

^d Ayrshire Central Hospital   (United Kingdom)

^e UNIVERSITY OF CHESTER   (United Kingdom)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Alzheimer's disease; Holo transcobalamin; Vitamin B12

Indexed keywords

COBALAMIN; CYANOCOBALAMIN; CYANOCOBALAMIN BINDING PROTEIN; TRANSCOBALAMIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENETIC POLYMORPHISM; GENETIC SIMILARITY; GENOTYPE; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN POLYMORPHISM; STATISTICAL SIGNIFICANCE;

AGED; AGING; ALZHEIMER DISEASE; APOLIPOPROTEINS E; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEX CHARACTERISTICS; SURVIVAL ANALYSIS; VITAMIN B 12;

EID: 12144286057     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076359     Document Type: Article

References (37)

1. 12 deficiency in primary degenerative dementia. Dementia 1990;1:272-277.
2. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H: Total serum homocysteine in senile dementia of Alzheimer type. Int J Ger Psych 1998;13:235-239.
3. 12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998;55:1449-1455.
4. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP: Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 2002;33:2351.
5. Lehmann M, Gottfries CG, Regland B: Identification of cognitive impairment in the elderly: Homocysteine is an early marker. Dement Geriatr Cogn Disord 1999;10:12-20.
6. McCaddon A, Hudson P, Davies G, Hughes A, Williams JHH, Wilkinson C: Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord 2001;12:309-313.
7. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA: Plasma homocysteine as a risk factor for dementia and Alzheimer's Disease. N Engl J Med 2002;346:476-483.
8. McCaddon A, Hudson P, Hill D, Barber J, Lloyd A, Davies G, Regland B: Alzheimer disease and total plasma aminothiols. Biol Psych 2002;in press.
9. 12 in Alzheimer-type dementia. Age Ageing 1984;13:101-105.
10. Karnaze DS, Carmel R: Low serum cobalamin levels in primary degenerative dementia. Arch Intern Med 1987;147:429-431.
11. 12 levels related to high activity of platelet MAO in patients with dementia disorders. Acta Psychiatr Scand 1988;78:451-457.
12. 12 deficiency. Age Ageing 1994;23:334-337.
13. 12 deficiency in Alzheimer's disease (letter). Arch Neurol 2000;57:607-608.
14. Carmel R: Measuring and interpreting holotranscobalamin (holo-transcobalamin II) (editorial). Clin Chem 2002;48:407-409.
15. 12 in Alzheimer's disease. Dement Geriatr Cogn Disord 2001;12:133-137.
16. Fràter-Schröder M, Hitzig WH, Butler R: Studies on Transcobalamin (TC). 1. Detection of TCII isoproteins in human serum. Blood 1979;53:193-203.
17. Daiger SP, Labowe ML, Parsons M, Wang L, Cavalli-Sforza LL: Detection of genetic variation with radioactive ligands. III. Genetic polymorphism of transcobalamin II in human plasma. Am J Hum Gen 1978;30:202-214.
18. Namour F, Guy M, Aimone-Gastin I, de Nonancourt M, Mrabet N, Guéant JL: Isoelectrofocusing phenotype and relative concentration of transcobalamin II isoproteins related to the codon 259 Arg/Pro polymorphism. Biochem Biophys Res Comm 1998;251:769-774.
19. Namour F, Olivier J-L, Abdelmouttaleb I, Adjalla C, Debard R, Salvat C, Gueant JL: Transcobalamin codon 259 polymorphism in HT-29 and Caco-2 cells and in Caucasians: relation to transcobalamin and homocysteine concentration in blood. Blood 2001;97:1092-1098.
20. Zetterberg H, Palmér M, Boreström C, Rymo L, Blennow K: The transcobalamin codon 259 polymorphism should be designated 776C>G, not 775G>C. Blood 2003;101:3749-3750.
21. McCaddon A, Blennow K, Hudson P, Regland B, Hill D: Transcobalamin polymorphism and homocysteine (letter). Blood 2001;98:3497-3499.
22. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, APA, 1994.
23. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatr 1984;141:1356-1364.
24. Folstein M, Folstein S, McHugh PR: Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS/ADRDA workgroup under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984;34:939-944.
26. Mirra SS, Heyman A, McKeel D: The consortium to establish a registry for Alzheimer's disease (CERAD). II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
27. Bogdanovic N, Morris JC: Diagnostic criteria for Alzheimer's disease in multi-centre brain banking; in Cruz-Sanchez FF, et al (eds): Neuropathological Diagnostic Criteria for Brain Banking. Biomedical and Health Research. New York, IOS Press, 1995, pp 20-29.
28. Blennow K, Ricksten A, Prince JA, Brookes AJ, Emahazion T, Wasslavik C, Bogdanovic N, Andreasen N, Batsman S, Marcusson J, Nagga K, Wallin A, Regland B, Olofsson H, Hesse C, Davidsson P, Minthon L, Jansson A, Palmqvist L, Rymo L: No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression. J Neural Transm 2000;107:1065-1079.
29. Ulleland M, Eilertsten I, Quadros EV, Rothenberg SP, Fedosov SN, Sundrehagen E, Orning L: Direct assay for cobalamin bound to transcobalamin (holo-transcobalamin) in serum. Clin Chem 2002;48:526-532.
30. Morris JA, Gardner MJ: Calculating confidence intervals for relative risks, odds ratios and standardised ratios and rate; in Gardner MJ, Altman DG (eds): Statistics with Confidence. London, British Medical Journal, 1992, pp 50-63.
31. Guo SW, Thompson EA: Performing the exact test of Hardy Weinberg Proportion for multiple alleles. Biometrics 1992;48:361-372.
32. 12 status in healthy older adults. Blood 2002;100:718-720.
33. Zetterberg H, Nexo E, Regland B, Minthon L, Boson R, Palmer M, Rymo L, Blennow K: The transcobalamin (TC) codon 259 genetic polymorphism influences holo-TC concentration in cerebrospinal fluid from patients with Alzheimer disease. Clin Chem 2003;49:1195-1198.
34. Smith AD: Homocysteine, B vitamins, and cognitive deficit in the elderly (editorial). Am J Clin Nutr 2002;75:785-786.
35. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, Van den Heuvel LP: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-113.
36. Van Der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, Van den Heuvel LP, Blom HJ: A second common mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neuraltube defects? Am J Hum Genet 1998;62:1044-1051.
37. Snowdon DA, Tully CL, Smith CD, Perez Riley K, Markesbery WR: Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: Findings from the Nun Study. Am J Clin Nutr 2000;71:993-998.